1) Busuishengxue granule
补髓生血颗粒剂
1.
Objective: This article discussed the clinical effective of Busuishengxue granule to chronic aplastic anemia (CAA) patients, and observed the difference in expression level of myelo-cytokine c-kit/CD117, c-Met/HGF and CD34~+ cell in CAA patients before and after treatment.
目的:探讨补髓生血颗粒剂对慢性再生障碍性贫血(以下简称为CAA)患者的临床疗效及治疗前后骨髓c-kit/CD117、HGF/c-met及CD34~+细胞表达水平的影响。
2.
Objective: This article discussed the clinical effect of Busuishengxue granule to chronic aplastic anemia (CAA) patients, and observed the different expression level of serum cytokine Interleukin-6 (IL-6) in CAA patients before and after treatment.
目的:探讨补髓生血颗粒剂对慢性再生障碍性贫血(以下简称为CAA)患者的临床疗效及其对治疗前后血清IL-6表达水平的影响,进一步揭示CAA发病机制及补肾中药治疗CAA的作用机理。
2) Marrow-supplementing and Blood-engendering Granule
补髓生血颗粒剂
1.
In this study, the regulating function of Marrow-supplementing and Blood-engendering Granule (MSABEG) on adhesion function in CAA was explored by observing it's effects on cell adhesion molecules and cytokines interrelated to adhesion.
本研究以细胞粘附分子VLA-4／CD_(49d)为切入点，以再障生血片为对照，观察了补髓生血颗粒剂对CAA粘附功能的调节作用。
2.
For testing the effects and discovering the mechanism of Marrow-supplementing and Blood-engendering Granule (MSABEG) working on CAA, 60 CAA patients were investigated at clinical therapeutic effectiveness and research on hematopoietic progenitor cell receptor and regulator.
为了进一步探讨补髓生血颗粒剂治疗慢性再生障碍性贫血的疗效和作用机制，本研究对60例CAA患者的临床疗效和有关造血祖细胞受体和调控因子进行了观察研究。
3) Busui Shengxue Granules
补髓生血颗粒
1.
Determination of Lcariin(C_(33)H_(40)O_(15))in Busui Shengxue Granules by RP-HPLC;
RP-HPLC法测定补髓生血颗粒中淫羊藿苷(C_(33)H_(40)O_(15))的含量
2.
To observe the effects and the mechanism of Busui Shengxue granules(补髓生血冲剂)to Chronic Aplastic Anemia(CAA).
目的:探讨补髓生血颗粒对慢性再生障碍性贫血(CAA)患者CD34+细胞及CD34+C-myc细胞表达影响及疗效机理。
4) Busui Shengxue Granule
补髓生血颗粒
1.
Effect of Busui Shengxue Granule on Serum Tyrosine Kinase 3 Ligand and Fibronectin in Patients with Chronic Aplastic Anemia;
补髓生血颗粒对慢性再生障碍性贫血患者血清酪氨酸激酶-3配体和纤维连接蛋白的影响
2.
Objective To observe the clinical effect of Busui Shengxue granule (BSSXG) in treating chronic aplastic anemia (CAA) and study its mechanism.
目的 观察补髓生血颗粒治疗慢性再生障碍性贫血(CAA)的临床疗效并探讨其作用机理。
3.
Objective: To observe the clinical effect of Busui Shengxue granule(BSSXG) in treating Myelodyplastic Syndrome-Refractory Anemia(MDS-RA),evaluate the expression of the blood IL-10 before and after treatment, and reveal the pathogenesis of MDS-RA and effect mecheanism of supplement BSSXG on MDS-RA.
目的：观察补髓生血颗粒治疗骨髓增生异常综合征之难治性贫(MDS-RA)的临床疗效，检测患者治疗前后血清IL-10表达的变化，进一步探讨补髓生血颗粒治疗MDS-RA的疗效及对IL-10的影响。
5) Busuishengxue granule
补髓生血颗粒
1.
The Clinical Effect and Experimental Study on Serum TNF-α of Patients with Chronic Aplastic Anemia Treated by Busuishengxue Granule;
补髓生血颗粒治疗慢性再生障碍性贫血的疗效及对患者血清TNF-α水平的影响
2.
The Clinical Effect and Experimental Study on the NF-κB of Signal Transduction with CAA Treated by Busuishengxue Granule;
补髓生血颗粒治疗慢性再障的疗效及对信号转导因子NF-κB的影响
3.
Objective: To observe the clinical effect of chronic aplastic anemia (CAA) treated with Busuishengxue granule (BSSXG) and the difference in expression levels of LFA-3/CD58, CD11b, Ln and IL-12 before and after treatment.
目的：观察补髓生血颗粒对慢性再障(CAA)的临床疗效及对粘附分子LFA-3／CD58、CD11b、Ln和细胞因子IL-12的影响。
6) Marrow-supplementing and Blood-engendering Granule
补髓生血颗粒
1.
Effects of Marrow-Supplementing and Blood-Engendering Granule on Bone Marrow and Peripheral Blood of Wistar Rats with Aplastic Anemia;
补髓生血颗粒对再障模型大鼠骨髓病理、造血祖细胞及外周血的影响
2.
Effects of Marrow-supplementing and Blood-engendering Granule Impacting Correlative Adhesion Molecule of Integrin VLA Family
补髓生血颗粒对慢性再障患者整合素VLA亚家族相关粘附分子的影响
3.
This experiment studied 60 rats models suffering from aplastic anemia in order to compare the difference between Marrow-supplementing and Blood-engendering Granule (MSABSEG)(high dose,moderate dose,low dose) and Aplastic Anemi.
本实验为观察补髓生血颗粒对于再生障碍性贫血模型大鼠的外周血细胞、骨髓有核细胞和粒系祖细胞的影响和作用,比较补髓生血颗粒组(高剂量、中剂量、低剂量)分别与再障生血片组治疗再障模型大鼠的上述三项指标的差异,并探讨补髓生血颗粒组(高剂量、中剂量、低剂量)与单纯性造模组相比对于上述三项指标的恢复情况,为此我们针对60只AA模型大鼠进行了观察研究。
补充资料：干流动剂、水悬性颗粒剂
分子式：
CAS号：
性质：又称干流动剂、水悬性颗粒剂。入水后，自动崩解，分散成悬浮液。它是在可湿性粉剂和悬浮剂的基础上发展起来的新剂型，它具有分散性好，悬浮率高、稳定性好、使用方便等特点，避开了可湿性粉剂产生粉尘，悬浮剂包装运输不便，贮藏易产生沉淀、结块、流动性差、粘壁等缺点。生产方法有喷雾造粒、悬式造粒、挤压造粒、高强度混合造粒、流化床造粒等。
CAS号：
性质：又称干流动剂、水悬性颗粒剂。入水后，自动崩解，分散成悬浮液。它是在可湿性粉剂和悬浮剂的基础上发展起来的新剂型，它具有分散性好，悬浮率高、稳定性好、使用方便等特点，避开了可湿性粉剂产生粉尘，悬浮剂包装运输不便，贮藏易产生沉淀、结块、流动性差、粘壁等缺点。生产方法有喷雾造粒、悬式造粒、挤压造粒、高强度混合造粒、流化床造粒等。
说明：补充资料仅用于学习参考，请勿用于其它任何用途。
参考词条